Obicetrapib – Medxy AI

Obicetrapib’s Impact on Lipoprotein(a) in High Cardiovascular Risk Patients: A Comprehensive Pooled Analysis

By MedXY 07/07/2026

Obicetrapib significantly lowers lipoprotein(a), LDL cholesterol, and apolipoprotein B in high cardiovascular risk patients, offering a promising addition to lipid-lowering therapies, especially for patients with mild to moderate Lp(a) elevation.

Cardiology Neurology news Specialties

Obicetrapib’s Role in Modulating Alzheimer’s Disease Biomarkers in Patients with Cardiovascular Disease: A Landmark Clinical Study

By MedXY 10/21/2025

Obicetrapib, a CETP inhibitor, lowers Alzheimer’s biomarkers like p-tau217 in ASCVD patients, especially ApoE4 carriers, suggesting a potential preventive strategy for high-risk individuals.

Cardiology news Specialties

Obicetrapib: A Promising Advance in LDL Cholesterol Lowering for High Cardiovascular Risk Patients

By MedXY 09/07/2025

Obicetrapib significantly reduces LDL cholesterol by nearly 30% in high-risk cardiovascular patients on maximal lipid therapy, with a safety profile comparable to placebo, representing a potential novel agent in managing familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Clinical Updates Diabetes & Endocrinology Neurology news Specialties

Obicetrapib Shows Promise in Slowing Alzheimer’s Disease Progression Through Lipid Modulation

By MedXY 08/17/2025

Obicetrapib, a CETP inhibitor, significantly slowed Alzheimer’s disease biomarker progression over 12 months and improved p-tau217 levels in APOE4 carriers while also benefiting lipid profiles in cardiovascular disease patients.